KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Revenue (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Revenue for 9 consecutive years, with $406.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 209.09% year-over-year to $406.6 million, compared with a TTM value of $874.8 million through Dec 2025, up 94.1%, and an annual FY2025 reading of $874.8 million, up 94.1% over the prior year.
  • Revenue was $406.6 million for Q4 2025 at Biocryst Pharmaceuticals, up from $159.4 million in the prior quarter.
  • Across five years, Revenue topped out at $406.6 million in Q4 2025 and bottomed at $92.8 million in Q1 2024.
  • Average Revenue over 3 years is $179.3 million, with a median of $145.5 million recorded in 2025.
  • The sharpest move saw Revenue tumbled 54.29% in 2024, then surged 209.09% in 2025.
  • Year by year, Revenue stood at $287.8 million in 2023, then crashed by 54.29% to $131.5 million in 2024, then soared by 209.09% to $406.6 million in 2025.
  • Business Quant data shows Revenue for BCRX at $406.6 million in Q4 2025, $159.4 million in Q3 2025, and $163.4 million in Q2 2025.